CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

M Vaghari-Tabari, P Hassanpour… - Cellular & Molecular …, 2022 - Springer
The CRISPR/Cas9 system is an RNA-based adaptive immune system in bacteria and
archaea. Various studies have shown that it is possible to target a wide range of human …

EGFR is a potential dual molecular target for cancer and Alzheimer's disease

HJ Choi, YJ Jeong, J Kim, HS Hoe - Frontiers in Pharmacology, 2023 - frontiersin.org
Many researchers are attempting to identify drugs that can be repurposed as effective
therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal …

Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic …

FAM Mohamed, HAM Gomaa, OM Hendawy, AT Ali… - Bioorganic …, 2021 - Elsevier
New EGFR inhibitor series of fifteen 5-chloro-3-hydroxymethyl-indole-2-carboxamide
derivatives has been designed, synthesized, and tested for antiproliferative activity against a …

[HTML][HTML] The role and therapeutic implication of endoplasmic reticulum stress in inflammatory cancer transformation

Y Li, L Lu, G Zhang, G Ji, H Xu - American Journal of Cancer …, 2022 - ncbi.nlm.nih.gov
Endoplasmic reticulum (ER) stress occurs when proteins are affected by various factors, fail
to fold properly into higher structures and accumulate in the lumen of the ER, which activates …

Application and prospect of CRISPR/Cas9 technology in reversing drug resistance of non-small cell lung cancer

L Huang, Z Liao, Z Liu, Y Chen, T Huang… - Frontiers in …, 2022 - frontiersin.org
Cancer drug resistance has always been a major factor affecting the treatment of non-small
cell lung cancer, which reduces the quality of life of patients. The clustered regularly …

The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts

H Liu, H Zeng, X Qin, W Ning, L Xu, S Yang, X Liu… - Protein & …, 2025 - academic.oup.com
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer
therapeutics that combine the specificity of monoclonal antibodies with the potency of …

Advances in renal cell carcinoma drug resistance models

Y Xiang, G Zheng, J Zhong, J Sheng, H Qin - Frontiers in Oncology, 2022 - frontiersin.org
Renal cell carcinoma (RCC) is the most common form of kidney cancer. Systemic therapy is
the preferred method to eliminate residual cancer cells after surgery and prolong the survival …

[HTML][HTML] Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer

B Liu, D Chen, S Chen, A Saber, H Haisma - Biochemical Pharmacology, 2020 - Elsevier
Several different mechanisms are implicated in the resistance of lung cancer cells to
epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), and only few have …

[HTML][HTML] Navigating the frontier: Comprehensive insights into CRISPR technology advancements, delivery strategies, and ethical considerations in cancer research

MS Jain, KS Srikruthi, P Goudanavar, NR Naveen - Oral Oncology Reports, 2024 - Elsevier
This review article provides a thorough exploration of the multifaceted landscape
surrounding CRISPR technology, with a specific focus on its evolution from genome editing …

Ten Years of CRISPRing Cancers In Vitro

D Capoferri, S Filiberti, J Faletti, C Tavani, R Ronca - Cancers, 2022 - mdpi.com
Simple Summary There are several ways to mimic cancer cells features, one of those being
permanently editing their DNA. Even though cancer cells alone cannot represent the whole …